Wall Street is not sold on the latest clinical results.
News & Analysis: Marinus Pharmaceuticals
A secondary offering on the way isn't what investors wanted to hear.
The small biopharma announced second-quarter 2018 results and gave a business update.
The tiny biopharma is back on the upswing following an analyst upgrade.
The biopharma's slide continues -- for good reason this time.
The key to big gains last year? Start off small.
Learn why these stocks fell in a strong market.
The tiny yet promising biopharma may be taken more seriously after today.
Investors are hoping a competitor's drug will pave the way for the company's own drug.
Success for Sage Therapeutics' postpartum depression drug bodes well for a related candidate from Marinus Pharmaceuticals.